Abstract: Aspects of the present disclosure provide methods, devices, and computer-readable storage media that support detection, effect monitoring, and recovery from failure modes in cloud computing application using a failure mode effect analysis (FMEA) engine. Historical metadata related to operation of a hierarchy of devices may be used as training data to train the FMEA engine to identify failure modes experienced by the hierarchy of devices. After training the FMEA engine, metadata from the hierarchy of devices may be input to the FMEA engine to identify a failure mode that may have occurred, and the FMEA engine may select a recovery process to recommend for addressing or mitigating the identified failure mode. In some implementations, the FMEA engine may output an indication of the recommended recovery process and/or initiate performance of one or more operations at the hierarchy of devices to recover from the failure event.

Abstract: A system and method for onboarding and managing assets in a decentralized identity network is disclosed. The method may include receiving an authorization proof from a member of a team of an enterprise to access an asset in the decentralized identity network. The method may further include validating the member of the team through a set of validator nodes. The method may further include provisioning the asset on the decentralized identity network. The method may further include onboarding the provisioned asset on the decentralized identity network. The method may further include generating a set of derived credentials of the onboarded asset. The method may further include validating a user access request corresponding to at least one of owners of an application and user to access the asset. The method may further include dynamically validating an employee access request from an employee and the unique asset DID to access the asset.

Abstract: The disclosure relates to system and method for managing security risk of information technology (IT) systems in an enterprise. The method includes determining valid trustware components that need to be evaluated for security risk of an IT system within the enterprise; correlating information associated with each of the valid trustware components in a set of data repositories; generating a mapping list comprising the valid trustware components, test cases corresponding to each of the valid trustware components, and test environments corresponding to each of the valid trustware components based on the correlation; triggering trustware security units for testing the valid trustware components based on the mapping list; and identifying security issues associated with the valid trustware components based on the testing. The trustware security units are arranged in a sequential manner or a parallel manner to align with execution of the test cases corresponding to each of the valid trustware components.

Abstract: The disclosure relates to system and method for managing security risk of information technology (IT) systems in an enterprise. The method includes determining valid trustware components that need to be evaluated for security risk of an IT system within the enterprise; correlating information associated with each of the valid trustware components in a set of data repositories; generating a mapping list comprising the valid trustware components, test cases corresponding to each of the valid trustware components, and test environments corresponding to each of the valid trustware components based on the correlation; triggering trustware security units for testing the valid trustware components based on the mapping list; and identifying security issues associated with the valid trustware components based on the testing. The trustware security units are arranged in a sequential manner or a parallel manner to align with execution of the test cases corresponding to each of the valid trustware components.

Abstract: The present disclosure relates to a method for preventing fraud in a trusted network. An information related to a plurality of fraudulent transactions are received from a plurality of entities in the trusted network. Each of the plurality of entities provides a consent for sharing the information related to corresponding plurality of fraudulent transactions. Indicators of Fraudulent Transactions (IOFT) metadata are generated based on one or more patterns in the information related to the plurality of fraudulent transactions. One or more IOFT data elements comprising transaction details associated with the plurality of fraudulent transactions and excluding confidential details are identified from the IOFT metadata. One or more IOFT data elements are transmitted in an encrypted format to the plurality of entities over the trusted network to prevent the fraud in the trusted network.

Abstract: The present disclosure discloses system and method for managing mobile assets using a decentralized network. The system comprises asset network, affiliated organization network and agent network. A managing application in agent network receives service request for one or more mobile assets from user. The service request is associated with purpose information and location information. Upon receiving service request, managing application retrieves mobile assets for service request from affiliated organization network upon verification of service request. Thereafter, managing application allocates mobile asset from one or more mobile assets for service request. Further, managing application provides first identifier to user and second identifier for allocated mobile asset. The first identifier and second identifier is presented by user and allocated mobile asset with each other.

Abstract: A system and method for controlling quality of performance of a digital application is disclosed. Performance data representing test results of a requested performance test on the application is obtained. A performance metric is optimized by analyzing the performance data and classifying analysis results of the analyzing into multiple categories, including an immediate remediation category. An automated modification is initiated based on a first analysis result classified into the immediate remediation category. An automated verification performance test determines a measure of improvement in performance of the application based on the modification by comparing a first verification result of a first performance test without the automated modification with a second verification result of a second performance test of the digital application with the automated front end modification.

Abstract: Methods and compositions are provided for delivery of therapeutic nucleic acids to a target cell. A chimeric antigen is provided to encapsulate, bind, or otherwise carry a nucleic acid molecule to a target cell where the chimeric antigen and nucleic acid are internalized, for example by receptor-mediated endocytosis. The chimeric antigen has a nucleic acid interaction domain, a target binding domain, and an immune response domain that may include a target antigen. Targeting is generally provided by the specificity of the target binding domain for a particular target cell receptor, but may also be provided by inclusion of a targeting antigen within the immune response domain. The combined delivery of chimeric antigen and nucleic acid, which may be a siRNA, may be synergistic in certain applications, for example in breaking host tolerance to a virus or in providing immunostimulation.

Abstract: Methods and compositions are provided for delivery of therapeutic nucleic acids to a target cell. A chimeric antigen is provided to encapsulate, bind, or otherwise carry a nucleic acid molecule to a target cell where the chimeric antigen and nucleic acid are internalized by receptor-mediated endocytosis. The chimeric antigen has a nucleic acid interaction domain, a target binding domain, and an immune response domain that may include a target antigen. Targeting is generally provided by the specificity of the target binding domain for a particular target cell receptor, but may also be provided by inclusion of a targeting antigen within the immune response domain. The combined delivery of chimeric antigen and nucleic acid, which may be a siRNA, may be synergistic in certain applications, for example in breaking host tolerance to a virus or in providing immunostimulation.

Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.

Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.

Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.

Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.

Abstract: Disclosed herein are the nucleotide sequences, deduced amino acid sequences as well as methods and compositions necessary to elicit immune responses against chronic Hepatitis B infections in animals and humans. Immune response is enhanced by fusing relevant viral antigens with xenotypic immunoglobulin heavy chain region through a peptide linker and producing the fusion proteins in Baculovirus expression system to incorporate high mannose glycosylation. By virtue of the antibody component, the fusion proteins bind to Fc receptors on the surface of antigen presenting cells, are taken up, processed and derived peptides are presented on MHC Class I, which elicit a CTL (Th1) response. In a similar fashion, due to cross priming and presentation on MHC Class II, will elicit a humoral (Th2) response. In addition, disclosed are the methods of cloning, expression and production of the fusion proteins.

Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.

Abstract: Disclosed herein are chimeric antigens, comprising an hepatitis C virus (HCV) antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is enhanced by presenting the host immune system with an immune response domain (HCV antigen from HVC core, envelope, or non-structural protein fragments) and a target binding domain (an Fc fragment). By virtue of the target binding domain, antigen presenting cells internalize and process the chimeric antigens for antigen presentation, thereby eliciting both a humoral and cellular immune response.

Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular, the compounds and methods elicit immune responses against foreign antigens that are otherwise recognized by the host as “self” antigens, thus breaking host tolerance to those antigens. Presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises an antibody fragment, enhances the immune response against the foreign or tolerated antigen. Antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response against the desired antigen.

Abstract: Methods and compositions are provided for delivery of therapeutic nucleic acids to a target cell. A chimeric antigen is provided to encapsulate, bind, or otherwise carry a nucleic acid molecule to a target cell where the chimeric antigen and nucleic acid are internalized by receptor-mediated endocytosis. The chimeric antigen has a nucleic acid interaction domain, a target binding domain, and an immune response domain that may include a target antigen. Targeting is generally provided by the specificity of the target binding domain for a particular target cell receptor, but may also be provided by inclusion of a targeting antigen within the immune response domain. The combined delivery of chimeric antigen and nucleic acid, which may be a siRNA, may be synergistic in certain applications, for example in breaking host tolerance to a virus or in providing immunostimulation.

Abstract: Disclosed herein are chimeric antigens, comprising an hepatitis C virus (HCV) antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is enhanced by presenting the host immune system with an immune response domain (HCV antigen from HCV core, envelope, or non-structural protein fragments) and a target binding domain (an Fc fragment). By virtue of the target binding domain, antigen presenting cells internalize and process the chimeric antigens for antigen presentation, thereby eliciting both a humoral and cellular immune response.

Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular, the compounds and methods elicit immune responses against foreign antigens that are otherwise recognized by the host as “self” antigens, thus breaking host tolerance to those antigens. Presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises an antibody fragment, enhances the immune response against the foreign or tolerated antigen. Antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response against the desired antigen.